The multi-targeted kinase inhibitor Sorafenib inhibits Enterovirus 71 IRES activity

被引：0
|
作者：
Peng, Y. [1 ]
Gao, M. [1 ]
Wang, X. [1 ]
Zhu, M. [1 ]
机构：
[1] Peking Univ, Hlth Sci Ctr, Beijing 100871, Peoples R China
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2014年 / 21卷
关键词：
D O I：
10.1016/j.ijid.2014.03.1356
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
64.026
引用
收藏
页码：453 / 453
页数：1
相关论文
共 50 条
  • [1] The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins
    Gao, Meng
    Duan, Hao
    Liu, Jing
    Zhang, Hao
    Wang, Xin
    Zhu, Meng
    Guo, Jitao
    Zhao, Zhenlong
    Meng, Lirong
    Peng, Yihong
    ANTIVIRAL RESEARCH, 2014, 106 : 80 - 85
  • [2] The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication
    Michaelis, Martin
    Paulus, Christina
    Loeschmann, Nadine
    Dauth, Stephanie
    Stange, Elisabeth
    Doerr, Hans Wilhelm
    Nevels, Michael
    Cinatl, Jindrich, Jr.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (06) : 1079 - 1090
  • [3] The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication
    Martin Michaelis
    Christina Paulus
    Nadine Löschmann
    Stephanie Dauth
    Elisabeth Stange
    Hans Wilhelm Doerr
    Michael Nevels
    Jindrich Cinatl
    Cellular and Molecular Life Sciences, 2011, 68 : 1079 - 1090
  • [4] Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sorafenib
    Kolb, E.
    Gorlick, Richard
    Houghton, Peter
    Morton, Christopher
    Maris, John
    Courtright, Joshua
    Carol, Hernan
    Lock, Richard
    Friedman, Henry
    Keir, Stephen
    Kang, Min
    Reynolds, C.
    Smith, Malcolm
    CANCER RESEARCH, 2009, 69
  • [5] Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program
    Keir, Stephen T.
    Maris, John M.
    Lock, Richard
    Kolb, E. Anders
    Gorlick, Richard
    Carol, Hernan
    Morton, Christopher L.
    Reynolds, C. Patrick
    Kang, Min H.
    Watkins, Amy
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (06) : 1126 - 1133
  • [6] SYNERGISTIC ANTITUMOR ACTIVITY OF THE COMBINATION OF THE MULTI-TARGETED TYROSINE KINASE INHIBITOR SORAFENIB AND OF EGFR INHIBITORS IN HUMAN COLON AND LUNG CANCER CELL
    Troiani, T.
    Martinelli, E.
    Morgillo, F.
    Orditura, M.
    De Vita, F.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 51 - 51
  • [7] Small Molecule Inhibits Enterovirus 71 Replication by Targeting the IRES Domain
    Davila-Calderon, Jesse
    Patwardhan, Neeraj
    Yuang-Chiu, Liang
    Sugarman, Andrew
    Cai, Zhengguo
    Penutmutchu, Srinivasa
    Li, Mei-Ling
    Brewer, Gary
    Hargrove, Amanda
    Tolbert, Blanton
    FASEB JOURNAL, 2020, 34
  • [8] Synergistic antitumor activity of the combination of the multi-targeted tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines
    Martinelli, E.
    Troiani, T.
    Laus, G.
    Pepe, S.
    Ciardiello, F.
    EJC SUPPLEMENTS, 2006, 4 (12): : 123 - 123
  • [9] Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models
    Tanaka, Ruriko
    Squires, Matthew S.
    Kimura, Shinya
    Yokota, Asumi
    Mallett, Kirsty
    Smyth, Tomoko
    Thompson, Neil T.
    Nagao, Rina
    Yamauchi, Takahiro
    Ushiki, Takashi
    Lyons, John F.
    Maekawa, Taira
    BLOOD, 2008, 112 (11) : 403 - 403
  • [10] Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity
    Howard, S.
    Berdini, V.
    Curry, J.
    Gill, A. L.
    Richardson, C. J.
    Rees, D.
    Reule, M.
    Tisi, D.
    Wyatt, P.
    Fazal, L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 93 - 93
12345